Genelux (NASDAQ:GNLX) Trading 3.3% Higher - What's Next?

Genelux Co. (NASDAQ:GNLX - Get Free Report)'s stock price shot up 3.3% on Thursday . The company traded as high as $2.55 and last traded at $2.53. 192,780 shares were traded during mid-day trading, an increase of 2% from the average session volume of 189,540 shares. The stock had previously closed at $2.45.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GNLX. Wall Street Zen lowered shares of Genelux from a "hold" rating to a "sell" rating in a research note on Friday. Benchmark cut their price target on Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Genelux in a research report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Genelux currently has an average rating of "Moderate Buy" and an average price target of $17.75.

Genelux Stock Performance

The firm has a market cap of $102.26 million, a price-to-earnings ratio of -2.85 and a beta of -0.49. The business's 50 day moving average price is $2.55 and its 200 day moving average price is $3.07.

Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. Sell-side analysts anticipate that Genelux Co. will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of Genelux

Several institutional investors have recently bought and sold shares of GNLX. Apollon Wealth Management LLC grew its stake in Genelux by 20.4% in the 4th quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock valued at $40,000 after acquiring an additional 2,857 shares during the period. LifeSteps Financial Inc. grew its stake in Genelux by 11.1% in the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock valued at $205,000 after acquiring an additional 8,715 shares during the period. Virtu Financial LLC acquired a new stake in shares of Genelux in the fourth quarter valued at about $25,000. Advisor Resource Council acquired a new stake in shares of Genelux in the first quarter valued at about $34,000. Finally, Miracle Mile Advisors LLC grew its position in shares of Genelux by 60.0% in the first quarter. Miracle Mile Advisors LLC now owns 40,000 shares of the company's stock valued at $108,000 after purchasing an additional 15,000 shares during the period. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.